Johnson & Johnson (NYSE:JNJ) is trading down 0.57% at 163.81
Johnson & Johnson (NYSE:JNJ) stock traded more than 1% up in Tuesday’s premarket on encouraging results from a phase-III real-world study on a booster dose of its Covid-19 vaccine.
The company said its booster shot is 94% effective when administered two months after the first dose. It said the booster increases antibody levels by four to six times relative to one shot.
Boosters given six months after the first shot appear to give even higher protection, the company said. All rises were irrespective of age, the company said.
J&J’s Covid-19 vaccine is the only one approved by western economies that is administered with a single dose.
Around 14.8 million Americans have received the company’s single-dose vaccine so far. The study included 390,000 people who received the J&J Covid-19 vaccine.
An advisory committee on Friday recommended Pfizer (NYSE:PFE) booster shots to people 65 years and older, along with other vulnerable population groups. A final decision from the Food and Drug Administration is expected any day now. The panel voted against endorsing Covid-19 booster shots widely, a plan that the Biden administration favoured.
On technical fronts Johnson & Johnson (NYSE:JNJ) RSI stood at 26.66 and currently stock is trading below all Moving Average. So, SELL position can be taken with following target and stoploss:
TRADE SIGNAL – : Johnson & Johnson (NYSE:JNJ) – SELL : 163.81, TARGET: 162.03, STOP LOSS : 165.25
